YD Bio Business Summary

YD Bio Ltd (YDES) is a clinical-stage biopharmaceutical company that generates revenue through a diversified model encompassing medical product sales, drug distribution, and clinical trial support services. As of early 2026, its primary revenue streams are derived from medical and related products (57.4%), pharmaceutical drugs (28.1%), and nutritional supplements. The company operates across three core segments: DNA methylation-based cancer diagnostics (OkaiDx), ophthalmologic regenerative therapies utilizing limbal stem cell (LSC) exosomes, and precision laboratory services provided through its CLIA/CAP-certified affiliate, EG BioMed. YD Bio competes directly with oncology diagnostic leaders such as Exact Sciences and Grail, as well as exosome-focused biotech firms like Coya Therapeutics and Aethlon Medical. Positioned as an emerging bridge between the Asian and North American markets, YD Bio is currently transitioning from platform validation to asset-level clinical development, supported by a newly established California operations hub and a robust 2026 roadmap for FDA IND submissions. The company is led by Founder, Chairman, and CEO Dr. Ethan Shen, a translational medicine expert with a pedigree including project management at Novartis and executive leadership at Yong Ding Biopharma. The executive suite includes Chief Financial Officer Edmund Hen, who previously directed corporate finance at Antelope Enterprise Holdings, and Chief Medical Officer Dr. Benjamin Zhang, a physician-scientist specializing in immune cell research and regenerative medicine. Following a governance restructuring in early 2026 to ensure Nasdaq compliance, the board now features prominent members such as Dr. Kochi Chang, Chairman of the Compensation Committee, and Dr. Shao-Da Lu, Chairman of the Nominating and Corporate Governance Committee. Major institutional backing is provided by YD Biopharma Holding Limited and EG Biomed Limited, which maintain majority voting control, alongside participation from institutional investors such as Geode Capital Management.